BrainStorm ALS treatment yields positive safety data
The company is said to be developing NurOwn to treat ALS which is a progressive neurodegenerative disease, Reuters reported. The researchers transplanted the patients with their own stem
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.